MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Cash Conversion Cycle 2011-2026 | EPZM
Annual Cash Conversion Cycle Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -308 | 102 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 | -308 | -103 |
Quarterly Cash Conversion Cycle Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -85.6 | -249 | - | -241 | -153 | -3.96 | -213 | -200 | -326 | -1.22 K | 54.5 | 41 | 39.7 | 131 | 189 | 153 | 153 | - | - | 3.49 | 3.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 189 | -1.22 K | -107 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.89 | - | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 15.9 | - | $ 50.8 M | USA |
 |
Evogene Ltd.
EVGN
|
-32.5 | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
-8.32 | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
67.1 | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
20.4 | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
213 | $ 8.44 | - | $ 76.2 M | USA |
 |
Immuron Limited
IMRN
|
867 | $ 0.81 | 0.3 % | $ 9.47 M |  Australia |
 |
Incyte Corporation
INCY
|
-54.7 | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
184 | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
19.9 K | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
24.6 | $ 23.05 | - | $ 1.55 B | USA |
 |
Jaguar Health
JAGX
|
289 | $ 7.88 | - | $ 18.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-816 | $ 26.67 | - | $ 1.44 B | Britain |
 |
Kamada Ltd.
KMDA
|
163 | $ 8.11 | - | $ 260 M | Israel |
 |
Krystal Biotech
KRYS
|
109 | $ 259.95 | - | $ 7.52 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 38.15 | - | $ 3.28 B | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |